1-(β-D-ribofuranosyl)-6-nitroindole | 62515-54-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 吲哚核糖核苷和核糖核苷酸
• 英文名称: 1-(β-D-ribofuranosyl)-6-nitroindole
• 英文别名: 1-β-D-ribofuranosyl-6-nitroindole；1-(β-D-Ribofuranosyl)-6-nitroindol；(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-nitroindol-1-yl)oxolane-3,4-diol
• CAS: 62515-54-2
• 化学式: C₁₃H₁₄N₂O₆
• 分子量: 294.264
• InChiKey: UXMWLUWSFFVNCB-FDYHWXHSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-O-三苯甲基-2,3-O-异亚丙基-D-呋喃核糖 在 manganese(IV) oxide 、 溶剂黄146 作用下， 以 乙醇 、 苯 为溶剂， 反应 34.5h， 生成 1-(β-D-ribofuranosyl)-6-nitroindole
  参考文献：
  名称：

  3-?-D-ribofuranosides (C-nucleosides) of indoles

  摘要：

  DOI：

  10.1007/bf00503480

文献信息

• SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS
  申请人：Matray Tracy J.

  公开号：US20150080564A1

  公开（公告）日：2015-03-19

  Synthesis and uses of conformationally restricted nucleomonomers (CRN) to prepare nucleic acid compounds. Methods for preparing nucleomonomers for nucleic acid compounds in high yields and in multi-gram scale for therapeutic modalities useful for treating or preventing diseases or disorders by up- or down-regulating the expression of genes and other nucleic acid based regulatory systems in a cell.

  合成和使用构象限制核苷单体（CRN）以制备核酸化合物。用于制备高产量和多克制剂的核苷单体的方法，用于治疗或预防疾病或紊乱，通过调节细胞内基因和其他核酸调控系统的表达来实现。
• Nucleic acid compounds for inhibiting VEGF family gene expression and uses thereof
  申请人：Marina Biotech, Inc.

  公开号：EP2468864A1

  公开（公告）日：2012-06-27

  The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing one or more VEGF family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more VEGF family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more VEGF family gene in a cell or in a subject to treat one or more VEGF family-related disease.

  本公开提供了能够降低或沉默一种或多种血管内皮生长因子家族基因表达的经双链核糖核酸分子（mdRNA）。本公开的 mdRNA 包括至少三条链，这些链结合形成至少两个非重叠的双链区，这些双链区被缺口或间隙隔开，其中一条链与一个或多个 VEGF 家族 mRNA 互补。此外，经双链可具有至少一个被 5-甲基尿苷取代的尿苷，以及可选的其他修饰或其组合。还提供了降低细胞或受试者中一种或多种 VEGF 家族基因表达以治疗一种或多种 VEGF 家族相关疾病的方法。
• Nucleic acid compounds for inhibiting WNT gene expression and uses thereof
  申请人：Marina Biotech, Inc.

  公开号：EP2471920A2

  公开（公告）日：2012-07-04

  The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing WNT1, WNT2, or WNT3A gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a WNT1, WNT2, or WNT3A mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a WNT1, WNT2, or WNT3A gene in a cell or in a subject to treat a WNT1, WNT2, or WNT3A-related disease.

  本公开提供了能够降低或沉默 WNT1、WNT2 或 WNT3A 基因表达的经双链核糖核酸分子（mdRNA）。本公开的 mdRNA 包括至少三条链，它们结合形成至少两个非重叠的双链区域，由缺口或间隙隔开，其中一条链与 WNT1、WNT2 或 WNT3A mRNA 互补。此外，经双链可具有至少一个尿苷，即 5-甲基尿苷、一个核苷，即锁定核酸，或可选的其他修饰，以及它们的任意组合。还提供了降低细胞或受试者中 WNT1、WNT2 或 WNT3A 基因表达以治疗 WNT1、WNT2 或 WNT3A 相关疾病的方法。
• Therapeutics with conformationally restricted monomers
  申请人：Marina Biotech, Inc.

  公开号：US10023863B2

  公开（公告）日：2018-07-17

  This invention provides single-stranded and multi-stranded compounds that are useful in various therapeutic modalities to regulate the expression of nucleic acid molecules in a cell. A range of compounds is provided, each containing one or more conformationally restricted nucleomonomers (CRN). In addition, compounds can contain one or more conformationally restricted nucleomonomers and one or more hydroxymethyl substituted nucleomonomers (unlocked nucleomonomers, UNA).

  本发明提供的单链和多链化合物可用于各种治疗方式，调节细胞中核酸分子的表达。 本发明提供了一系列化合物，每种化合物都含有一种或多种构象受限核单体（CRN）。 此外，化合物还可含有一种或多种构象受限核单体和一种或多种羟甲基取代核单体（解锁核单体，UNA）。
• Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
  申请人：SIRNA THERAPEUTICS, INC.

  公开号：US10584335B2

  公开（公告）日：2020-03-10

  The instant disclosure features single-stranded RNA molecules comprising one or more internal, non-nucleotide spacers. A non-nucleotide spacer covalently links nucleotide portions of the molecule. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism and, thus, represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.

  本公开的单链 RNA 分子包含一个或多个内部非核苷酸间隔物。非核苷酸间隔共价连接分子的核苷酸部分。单链 RNA 分子具有导向链或反义链的功能，能够通过 RNA 干扰机制抑制基因表达，因此是单链 RNAi 制剂。单链 RNAi 分子可用于各种治疗、诊断、目标验证、基因组发现、基因工程和药物基因组学应用。